Oncology medicine manufacturer Venus Remedies Ltd, has extended its reach in the Association of Southeast Asian Nations (ASEAN) region, South America and Eastern Europe with marketing approvals for key cancer drugs from Philippines, Paraguay, Georgia and Moldova.
With this, the company has secured 506 marketing approvals for its oncology products across 76 countries.
Venus Remedies has secured marketing approval for topotecan from Philippines, the second largest market in ASEAN. The company has also got product registration for irinotecan in Paraguay, docetaxel in Georgia and topotecan and irinotecan in Moldova.
Venus Remedies has already submitted dossiers to the Health Ministry of the Philippines government for another 50-odd marketing authorisations, and most of these pending approvals are for oncology products.
Venus Remedies also expects the marketing approval for irinotecan in Paraguay to facilitate the registration process for its oncology drugs in other South American countries as well, considering that many of them have similar regulatory processes.
Similarly, the marketing authorisation for docetaxel from Georgia and topotecan and irinotecan from Moldova will enable the company to further consolidate its position in Eastern Europe and the Balkans region, where it had recently secured its first marketing authorisation from Bosnia for a chemotherapy drug.